Your browser doesn't support javascript.
loading
Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation.
Corbeil, Olivier; Essiambre, Anne-Marie; Béchard, Laurent; Roy, Audrey-Anne; Huot-Lavoie, Maxime; Brodeur, Sébastien; Chandrasena, Ranjith; Thériault, Chantale; Crocker, Candice; Melun, Jean-Pierre; Tibbo, Phil; Demers, Marie-France; Roy, Marc-André.
Afiliación
  • Corbeil O; Faculty of Pharmacy, Université Laval, 1050 Av. de la Médecine, Quebec City, QC G1V 0A6, Canada.
  • Essiambre AM; Quebec Mental Health University Institute, Quebec City, QC, Canada.
  • Béchard L; CERVO Brain Research Centre, Quebec City, QC, Canada.
  • Roy AA; CERVO Brain Research Centre, Quebec City, QC, Canada.
  • Huot-Lavoie M; School of Psychology, Université Laval, Quebec City, QC, Canada.
  • Brodeur S; Faculty of Pharmacy, Université Laval, Quebec City, QC, Canada.
  • Chandrasena R; Quebec Mental Health University Institute, Quebec City, QC, Canada.
  • Thériault C; CERVO Brain Research Centre, Quebec City, QC, Canada.
  • Crocker C; Faculty of Medicine, Université Laval, Quebec City, QC, Canada.
  • Melun JP; CERVO Brain Research Centre, Quebec City, QC, Canada.
  • Tibbo P; Faculty of Medicine, Université Laval, Quebec City, QC, Canada.
  • Demers MF; Quebec Mental Health University Institute, Quebec City, QC, Canada.
  • Roy MA; CERVO Brain Research Centre, Quebec City, QC, Canada.
Ther Adv Psychopharmacol ; 12: 20451253221136021, 2022.
Article en En | MEDLINE | ID: mdl-36405400
Background: Non-adherence to antipsychotics in schizophrenia is associated with an increased risk of psychotic relapse and hospitalization, a risk that is reduced with the use of long-acting injectable (LAI) antipsychotics. Randomized clinical trials (RCTs) have demonstrated the efficacy of paliperidone palmitate 3-monthly (PP3M) for psychotic relapse prevention in schizophrenia, but it remains poorly documented among individuals treated in real-life settings who can benefit the most out of LAIs. Objectives: The objective of this study was to evaluate the effectiveness of PP3M in relapse prevention among patients with schizophrenia. Methods: This is a multicentre retrospective study conducted in four outpatients' clinics across Canada. All consecutive patients with a main diagnosis of schizophrenia who initiated PP3M between June 2016 and March 2020 were included. The primary outcome was psychotic relapse, defined using broad and clinically relevant criteria. Results: Among 178 consecutive patients who were switched to PP3M, the 12-month relapse rate was 18.5% and the relapse-free survival probability was 0.788 (95% confidence interval [CI] = 0.725-0.856). Comorbid diagnoses of personality disorders and substance use disorders were associated with hazard rates (HRs) of 3.6 (95% CI = 1.8-7.3, p < 0.001) and 3.1 (95% CI = 1.6-6.2), respectively. Increased psychopathology severity was associated with an increased likelihood of relapse, while having a job or being in school was protective. Conclusion: These findings reinforce the necessity of conducting research in patients with comorbid psychiatric disorders who are typically underrepresented in RCTs, yet overrepresented in real-life settings, in order to better inform and guide clinical practice.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Observational_studies / Risk_factors_studies Idioma: En Revista: Ther Adv Psychopharmacol Año: 2022 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Observational_studies / Risk_factors_studies Idioma: En Revista: Ther Adv Psychopharmacol Año: 2022 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Reino Unido